Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging
about
Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade gliomaDCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Dynamic contrast-enhanced MRI: Study of inter-software accuracy and reproducibility using simulated and clinical data.PKQuest_Java: free, interactive physiologically based pharmacokinetic software package and tutorial.Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat gliomaA theoretical framework for determining cerebral vascular function and heterogeneity from dynamic susceptibility contrast MRIAssessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapyVessel architectural imaging identifies cancer patient responders to anti-angiogenic therapyAssessment of DCE-MRI parameters for brain tumors through implementation of physiologically-based pharmacokinetic model approaches for Gd-DOTA.Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients.T2*-correction in dynamic contrast-enhanced MRI from double-echo acquisitions.Sampling requirements in DCE-MRI based analysis of high grade gliomas: simulations and clinical results.
P2860
Q26826862-F95610DD-F881-4F8E-A945-A00FE99857DCQ30687678-8B2F8446-AD2D-4013-AFC7-4C9C8E6600EEQ30847284-427CF7B6-9201-4D3B-B441-2AE8140D789CQ31033043-C73A61EF-A537-4257-AD70-CA4F9D0170E9Q33490823-D5E880D2-00A5-477D-BF62-20C387EB8F7CQ33525581-4A514391-1B2B-4A95-BF4E-A9ECCD7A31AFQ33727635-38FAD112-4B15-490A-B645-7A1F531354CCQ33888366-E034A8A0-D4DF-499E-9B24-D4E6C27A196CQ34517492-C8217268-5616-49E7-AEE6-5C95EE917E57Q35673015-1C104721-2A3C-4857-B0D3-42D372D8BDA2Q37042355-A3AC4D80-181F-4240-BDAF-34F9D68E2D86Q37161504-8C406892-C3F4-4609-A732-1FC382BCC7DFQ39372575-62F766AC-90E0-466A-B9E6-D086A089D172Q40960183-0856B5D9-9079-42E5-9008-D4173B10179DQ45226683-A841CA55-915A-43A4-A402-1BA7E6129D60Q48327067-0F3989C8-9DC1-445E-BE04-853D641C4AF1
P2860
Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of three physiologi ...... measured by dynamic MR imaging
@en
Comparison of three physiologi ...... easured by dynamic MR imaging.
@nl
type
label
Comparison of three physiologi ...... measured by dynamic MR imaging
@en
Comparison of three physiologi ...... easured by dynamic MR imaging.
@nl
prefLabel
Comparison of three physiologi ...... measured by dynamic MR imaging
@en
Comparison of three physiologi ...... easured by dynamic MR imaging.
@nl
P2093
P2860
P356
P1476
Comparison of three physiologi ...... measured by dynamic MR imaging
@en
P2093
Benjamin L Viglianti
James R MacFall
Mark W Dewhirst Dvm
P2860
P304
P356
10.1002/JMRI.21344
P577
2008-06-01T00:00:00Z